Patient Support

Cryoport's business unit, Cryogene, will be tasked with helping to foster the growth of Moffitt’s cell and gene therapy efforts.

The collaboration is powered by the discovery and development of obesity, type 2 diabetes, and cardiovascular disease treatments.

The new form of the vaccine would remove the need for HCPs to combine the powder antigen and liquid adjuvant themselves prior to administering.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jon Kostas, executive director, Association for Prescription Psychedelics (APP), describes the randomized clinical trial involving psilocybin that he participated in.

What is the value in US adults addressing these risks, and how do social determinants of health play a role?

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jon Kostas, executive director, Association for Prescription Psychedelics (APP), addresses the importance of stopping the spread of misinformation when it comes to psychedelics.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jon Kostas, executive director, Association for Prescription Psychedelics (APP), explains why this resource is an asset, specifically for research in the psychedelic space.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jon Kostas, executive director, Association for Prescription Psychedelics (APP), provides a peek into what the association has set out to accomplish.

A forum intended for HCPs, policy experts, and industry leaders addresses pressing obstacles facing this sector of the industry today.

Is this level of involvement with HRSNs associated with higher burnout?

A dive into the top articles in this sector making waves this year.

Cheryl Allen, BS Pharm, MBA, founding partner, Curatio Scientia Advisors, discusses "Enhancing Patient Access and Support Through Technology: A Comprehensive Assessment," and upcoming industry challenges.

A session provides considerations for manufacturers during development, rollouts, and implementation, specifically as it pertains to the HSSP perspective.

Kevin O’Meara discusses Patient-Cetric 3.0 breakout session and the challenges of drug manufactures implementing Direct-to-Patient models.

A case study explores a way to potentially transform commercial organizations, while driving revenue growth.

A panel uncovers how distribution channels are aligning commercialization efforts.

Filling the gaps in the patient journey within an increasingly complex data environment.

A guide to overcoming the top obstacles facing patient services programs today.

Is the potential of a more formal policy integration for health issues and disease prevention a scary suggestion or a good idea?

While the program could be a good option for many, it's not a panacea.

A qualitative analysis consisting of patients, care partners, and oncology clinicians measures the sources of time burdens, along with how these impact various individuals.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Chase Feiger, MD, co-founder, Ostro, outlines the trends he expects to see over the next 10-15 years when it comes to the intersection of AI and life sciences.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Chase Feiger, MD, co-founder, Ostro, discusses the value of AI technology when it comes to tackling digital commercialization challenges.

The media company utilized CMS data and worked with Medicare experts to pinpoint qualities that were highly valued to consumers.

Could health system changes that improve patient access to medication have a positive effect on societal welfare?

What are their satisfaction rates when it comes to telemedicine visits?

The collaboration ultimately benefits oncology patients, as life science companies will be able to access their cancer journey data more efficiently.

By 2050, study estimates that cancer incidence and mortality rates will nearly triple in low-Human Development Index countries, highlighting an urgent need for enhanced global cancer prevention, early detection, and treatment strategies to address growing disparities.

With today's pharmacy landscape shaken by unprecedented and wider disruption to healthcare support and delivery, community and independent entities strive to remain an integral cog in the mix.

With great power comes great responsibility. In this case, tackling these obstacles is vital to making sure that the positives of GLP-1s are not outweighed by the downfalls of improper waste disposal.